Progenics Pharmaceuticals, Inc.

Progenics Pharmaceuticals, Inc. is a biopharmaceutical company that develops and commercializes innovative treatments for cancer and viral diseases.
Products in the Progenics pipeline induce an immune response, or mimic natural immunity, to fight lethal diseases, with an initial focus on malignant melanoma and HIV infection. The Company's therapeutic, antigen-based cancer vaccine is the first to enter Phase III clinical trials. Progenics also in-licenses promising technologies and product candidates from other companies. Progenics' collaborations with leading pharmaceutical companies help support later stage clinical trials and assist in bringing products to market.
By initiating clinical trials prior to establishing marketing collaborations, Progenics is able to optimize its revenue share from marketed products, thus providing increased value to its shareholders.

Activity:

- Manufacturing
- Research & Development

Product / Technology type(s) covered:

- Bio
- Pharmaceuticals / Therapeutics

Therapeutic targets:

- Cancer
- Dermatology
- Infectious Diseases

Markets Covered

a. HeadQuarter:

b. Continent(s) active:

c. Countries active:

Corporate data:

Number of Employees:

Turnover:

Amount:	Year:	Currency:

Year founded: